Table 3.
Demographic, clinical, and target organ damage characteristics of normal versus hyperuricemic among males and females
| Males | Females | |||||
|---|---|---|---|---|---|---|
| Normal SUA | Hyperuricemic | P‐value | Normal SUA | Hyperuricemic | P‐value | |
| Number (n) | 195 | 50 | 166 | 11 | ||
| Age (y) | 51.6 (12.6) | 57.2 (12.1) | 0.005 | 53.2 (13.3) | 62.5 (10.9) | 0.026 |
| Systolic BP (mm Hg) | 142.0 (17.3) | 143.3 (17.7) | 0.62 | 140.9 (18.3) | 142.0 (16.5) | 0.84 |
| Δ Systolic BP (mm Hg) | ‐7.5 (16.8) | ‐11.6 (20.7) | 0.14 | ‐11.1 (20.6) | 0.2 (28.2) | 0.088 |
| Diastolic BP (mm Hg) | 87.6 (10.9) | 87.3 (10.4) | 0.86 | 86.1 (10.7) | 80.0 (11.0) | 0.067 |
| Δ Diastolic BP (mm Hg) | ‐6.9 (12.0) | ‐8.8 (11.1) | 0.31 | ‐9.0 (12.6) | ‐4.0 (13.5) | 0.20 |
| Heart Rate (bpm) | 65.1 (11.5) | 65.9 (11.4) | 0.66 | 67.3 (10.4) | 66.3 (13.9) | 0.76 |
| BMI (Kg/m2) | 27.2 (3.5) | 27.5 (3.2) | 0.61 | 26.2 (4.7) | 31.0 (5.6) | 0.001 |
| Smoking (%) | 35 (18%) | 4 (8%) | 0.084 | 23 (14%) | 0 (0%) | 0.36* |
| Diabetes (%) | 13 (7%) | 3 (6%) | 1.00* | 8 (5%) | 4 (36%) | 0.003* |
| Glucose (mg/dL), median (IQR) | 86 (79, 94) | 86 (82, 95) | 0.63** | 82.0 (76.0, 89.0) | 95.0 (80.0, 124.0) | 0.032** |
| Triglycerides (mg/dL), median (IQR) | 105 (79, 143) | 152 (93, 233) | <0.001** | 91.0 (71.0, 126.0) | 175.0 (107.0, 280.0) | <0.001** |
| Total cholesterol (mg/dL) | 191.6 (33.6) | 200.9 (34.1) | 0.099 | 200.3 (34.3) | 206.2 (24.7) | 0.58 |
| HDL cholesterol (mg/dL) | 49.2 (11.1) | 45.7 (12.3) | 0.077 | 59.8 (13.7) | 47.1 (12.8) | 0.003 |
| LDL‐cholesterol (mg/dL) | 118.2 (30.3) | 118.5 (34.6) | 0.96 | 119.6 (32.2) | 121.0 (27.4) | 0.89 |
| Creatinine (mg/dL) | 0.9 (0.2) | 1.0 (0.2) | 0.001 | 0.7 (0.1) | 0.9 (0.2) | 0.007 |
| Glomerular Filtration Rate <60 mL/min (%) | 6 (3%) | 6 (12%) | 0.011 | 5 (3%) | 2 (18%) | 0.016 |
| Drugs (%): | ||||||
| ACE inhibitors | 57 (29%) | 19 (38%) | 0.23 | 41 (25%) | 5 (45%) | 0.16* |
| Angiotensin receptor blockers | 59 (30%) | 15 (30%) | 0.97 | 39 (23%) | 3 (27%) | 0.72* |
| Beta‐blockers | 37 (19%) | 10 (20%) | 0.87 | 39 (23%) | 8 (73%) | 0.001* |
| Calcium channel antagonist | 73 (37%) | 17 (34%) | 0.65 | 41 (25%) | 3 (27%) | 1.00* |
| Alpha‐blockers | 19 (10%) | 10 (20%) | 0.045 | 19 (11%) | 2 (18%) | 0.62* |
| Diuretics | 56 (29%) | 22 (44%) | 0.039 | 44 (27%) | 8 (73%) | 0.003* |
| Statins | 22 (11%) | 12 (24%) | 0.020 | 15 (9%) | 1 (9%) | 1.00* |
ΔSBP and DBP represented the difference between the measurement at follow‐up and at baseline. Median follow‐up time was 3.85 y.
Abbreviations: ACE, angiotensin‐converting enzyme; BMI, body mass index; BP, blood pressure; HDL, high‐density lipoprotein; IQR, interquartile range; LDL, low‐density lipoprotein.
*
Fisher's exact test.
**
Wilcoxon rank‐sum test.